Opendata, web and dolomites

TRACER SIGNED

TRAF-STOP therapy to reduCe inflammation in athERosclerosis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRACER project word cloud

Explore the words cloud of the TRACER project. It provides you a very rough idea of what is the project "TRACER" about.

treatment    pipeline    founders    underlying    mini    seed    cardiovascular    implications    cd40l    suppression    modeled    venture    lowering    inflammatory    therapeutics    downstream    tolerated    grant    immune    atherosclerosis    first    oral    interaction    molecule    cartesio    hypothesis    pursue    majority    inhibition    dyad    found    mediators    risk    model    traf6    lutgens    ing    pass    tested    ligand    relative    lipid    animal    poc    signaling    capital    reduce    translational    treat    despite    termed    thromboembolic    solid    candidates    drug    driving    hold    reduces    scientific    traf    atherosclerotic    cd40    domain    clinical    excellent    significantly    company    force    stimulatory    hands    inhibitors    events    therapeutic    arteries    blocking    portfolio    disease    characterizing    toxicology    plan    start    poses    binding    investment    25    bio    mice    vast    receptor    ready    valorise    tnf    virtual    stops    diseases    small    pig    unaddressed    patent    bind    co    screening    business    prof   

Project "TRACER" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM 

Organization address
address: MEIBERGDREEF 15
city: AMSTERDAM
postcode: 1105AZ
website: www.amc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

Atherosclerosis, the underlying cause of the majority of cardiovascular diseases, is a lipid driven, inflammatory disease of the large arteries. Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the vast majority of atherosclerosis induced cardiovascular disease risk remains unaddressed. Therefore, characterizing mediators of the inflammatory aspect of atherosclerosis is a widely recognized scientific goal with great therapeutic implications. Blocking the co-stimulatory CD40L-CD40 dyad reduces atherosclerosis. However, long-term inhibition of CD40L or its receptor CD40 results in suppression of the immune system and poses a risk for thromboembolic events. Therefore, we focused on the downstream signaling pathways of CD40, and found that the interaction between CD40 and TNF-receptor-associated factor 6 (TRAF6) is the driving force for atherosclerosis. Using virtual ligand screening, we identified several small molecule inhibitors termed TRAF-STOPs that were modeled to bind to the CD40-binding domain of TRAF6. TRAF-STOPs significantly reduce (existing) atherosclerosis and treatment was well tolerated. The first toxicology results in mice show that there are no side effects. Here we pursue the hypothesis that TRAF-STOPs are excellent candidates to pass the translational pipeline towards a clinical application to treat atherosclerotic cardiovascular disease. Prof. Lutgens is one of the founders of the recently established start-up company Cartesio Therapeutics to be able to valorise our novel TRAF-STOPs. By the end of the PoC grant, we expect to have an oral drug available and to have completed toxicology and bio-distribution analysis in a large animal model (mini-pig) and have tested TRAF-STOPs in a pig model of atherosclerosis. This way, we hold a solid business case in our hands. The resulting business- and (pre-)clinical development plan and patent portfolio will then be ready for seed investment and venture capital funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

TRUST (2018)

Truth and Semantics

Read More